Develops cancer immunotherapies for solid tumors and ovarian cancer.
Dec 2025Revenue $72.8M/yrExpenses $41.4M/yr
Reached break-even Apr 2025
Figures by year
When did Compugen become profitable?
Its revenue passed its expenses in Apr 2025. In the 12 months to Dec 2025, revenue was $72.8M and expenses $41.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $72.8M | $41.4M | $31.3M |
| Dec 2024 | $27.9M | $42.8M | −$14.9M |
| Dec 2023 | $33.5M | $46.5M | −$13.0M |
| Dec 2022 | $7.50M | $42.9M | −$35.4M |
| Dec 2021 | $6.00M | $41.1M | −$35.1M |
| Dec 2020 | $2.00M | $33.5M | −$31.5M |
| Dec 2018 | $17.8M | $41.0M | −$23.2M |
| Dec 2016 | $712K | $33.3M | −$32.6M |
| Dec 2015 | $9.28M | $30.2M | −$20.9M |
| Dec 2014 | $12.4M | $24.7M | −$12.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.